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Objectives: To clarify the contemporary clinical outcome of stage I seminoma and to provide information on treatment
options to patients.
Methods: Aretrospectiveanalysisof425patientswhounderwentorchiectomyforstageIseminomabetween1985and
2006 at 25 hospitals in Japan. Relapse-free survival rates were calculated using the Kaplan–Meier method and clinico-
pathological factors associated with relapse were examined by univariate and multivariate analyses using the Cox pro-
portional hazards model.
Results: Atotalof30outof425patientshadrelapsed.Relapse-freesurvivalratesat10 yearswere79,94and94%inthe
surveillance, chemotherapy and radiotherapy groups, respectively. Post-orchiectomy management and rete testis inva-
sion were identiﬁed as independent predictive factors associated with relapse. Rete testis invasion remained to be an
independent predictive factor, even if the cases with relapses in the contralateral testis were censored. Only one patient,
who relapsed after adjuvant radiotherapy, died of the disease. Overall survival at 10 years was 100, 100 and 99% in the
surveillance, chemotherapy and radiotherapy groups, respectively. More than half of the patients were lost to follow up
within 5 years.
Conclusions: The outcome of Japanese patients with stage I seminoma is similar to previously published Western
reports. Surveillance policy is becoming a popular option in Japan, although the relapse rate in patients opting for
surveillance policy is higher than those opting for adjuvant chemotherapy or radiotherapy. Rete testis invasion is an
independentpredictivefactorassociatedwithrelapseregardlessofthepost-orchiectomymanagement.Long-termfollow
up is mandatory for detection of late relapse.
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Introduction
Approximately 75% of seminoma patients present with
stage I disease.
1 After orchiectomy, stage I seminoma
patients can be managed by surveillance, adjuvant radio-
therapy or adjuvant chemotherapy. Almost all patients can
be salvaged, even after a relapse, mainly by chemotherapy;
the overall cure rates approach 100%, regardless of the post-
orchiectomy management.
2,3
Because the incidence of testicular germ cell tumors has
been rising in Japan,
4,5 even though it is still lower than that
in Western countries, we should pay more attention to this
disease. However, little is known about post-orchiectomy
management patterns and predictive factors associated with
relapse in the Japanese population with stage I seminoma.
6–8
In the present study, we carried out a retrospective multi-
institutional survey to establish the clinical outcome and
predictive factors for relapse of stage I seminoma, and to
provide information on treatment options to patients.
Methods
We registered 425 testicular cancer (TC) patients diagnosed
with stage I seminoma who underwent radical orchiectomy
between 1985 to 2006 at 25 Japanese institutions, including
three university hospitals. We collected clinical and patho-
logical data from the medical records including age at
orchiectomy and pathological information, such as pT stage,
tumor size, presence or absence of anaplastic feature, syn-
cytiotrophoblastic cells, lymphovascular invasion, rete testis
invasion or spermatic cord invasion. We also gathered
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nosis, post-orchiectomy management, relapse pattern, death
and the patient’s follow-up schedule. The signiﬁcance of
difference in the age at orchiectomy was assessed using
ANOVA.The signiﬁcance of differences in the distribution of
clinicopathological characteristics or relapse pattern among
the post-orchiectomy management groups was determined
by Pearson’s c
2-test or Fisher’s exact test, respectively.
The primary end-point was relapse-free survival (RFS)
calculated from the date of orchiectomy to that of a diagno-
sis of any relapse, including a relapse in the contralateral
testis, death from any cause or last follow up.To estimate the
hazard ratio (HR) and to identify the predictive factors asso-
ciated with RFS, we carried out univariate and multivariate
analyses with backward elimination using the Cox propor-
tional hazards model.A two-sided P < 0.05 was regarded as
statistically signiﬁcant.
Results
Patient characteristics
The characteristics of 425 patients with stage I seminoma
are presented in Table 1. Surveillance policy was provided
to 186 patients, adjuvant chemotherapy to 57 and adjuvant
radiotherapy to 182 as post-orchiectomy management. The
median age at orchiectomy was higher in the adjuvant che-
motherapy group (40 years) than in the surveillance
(36 years) and adjuvant radiotherapy (36 years) groups, but
the difference was not statistically signiﬁcant. The median
follow up duration of the entire study group was
52.5 months (range 0.1–248.5 months); it was shorter in the
surveillance group (44.9 months) than in the adjuvant
chemotherapy (58.4 months) and radiotherapy group
(60.8 months).
Until 1990, 89.4% of TC patients were treated with adju-
vant radiotherapy after orchiectomy. However, the propor-
tion continued to decrease, resulting in 25.2% in the 2000s.
Meanwhile, 8.5% of the patients were managed with a sur-
veillance policy before 1990, but the proportion increased to
59.2% in the 2000s. Before 1990, only one patient was
treated with adjuvant chemotherapy. In the 1990s, the pro-
portion of patients treated with adjuvant chemotherapy was
increasing and it reached 15.5% in the 2000s.
Regimens of adjuvant chemotherapy were single-agent
carboplatin in 51 patients (89.5%); etoposide and cisplatin
in one patient (1.8%), bleomycin, etoposide and cisplatin in
one patient (1.8%), and cisplatin, vinblastine and bleomycin,
or vinblastine, actinomycin-D and bleomycin in four
patients (7.0%). The ﬁelds of irradiation in adjuvant radio-
therapy were para-aorta and ipsilateral pelvis in 130 patients
(71.4%), para-aorta and bilateral pelvis in 18 patients
(9.9%), para-aorta alone in 11 patients (6.0%) and unspeci-
ﬁed in 23 patients (12.6%).
The distribution of clinicopathological characteristics
according to post-orchiectomy management is listed in
Table 2. The proportion of the patients with pT1 seminoma
was signiﬁcantly higher in the surveillance group (85.8%)
than in the chemotherapy (63.8%) or radiotherapy group
(76.2%). The patients with anaplastic seminoma or sper-
matic cord invasion were more frequently treated with adju-
vant chemotherapy (10.9, 10.6%) or radiotherapy (6.3,
6.5%) than by surveillance (2.5, 1.9%). The distribution of
other factors was similar among the three groups.
Pattern of relapse and treatment on relapse
During the follow up duration, 30 patients experienced a
relapse of the disease, including 19 patients in the surveil-
lance group, two patients in the chemotherapy group and
nine patients in the radiotherapy group. The pattern of
relapse and treatment on relapse in these patients is summa-
rized in Table 3.
Table 1 Patient characteristics
Total Post-orchiectomy management P*
Surveillance Chemotherapy Radiation
No. patients 425 186 57 182
Median age at orchiectomy, year (range) 36 (19–84) 36 (19–84) 40 (24–66) 36 (22–64) 0.084
Median follow up, months (range) 52.5 (0.1–248.5) 44.9 (0.1–218.7) 58.4 (2.5–205.6) 60.8 (0.9–248.5)
Post-orchiectomy management pattern by the year of orchiectomy
1985–1989 47 4 (8.5%) 1 (2.1%) 42 (89.4%)
1990–1994 63 21 (33.3%) 8 (12.7%) 34 (54.0%)
1995–1999 109 39 (35.8%) 16 (14.7%) 54 (49.5%)
2000–2006 206 122 (59.2%) 32 (15.5%) 52 (25.2%)
*ANOVA.
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21.0 months in the surveillance group, 42.8 months in the
chemotherapy group and 37.9 months in the radiotherapy
group.A total of 24 out of 30 relapses (80%) were diagnosed
within 5 years from orchiectomy. Late relapse was observed
more than 5 years after orchiectomy in four patients (21.1%)
in the surveillance group and two patients (22.2%) in the
radiotherapy group.
The retroperitoneum was the main site of relapse in the
surveillance group (78.9%) and the chemotherapy group
(100%), whereas the mediastinum and lung were the pre-
dominant sites of relapse in the radiotherapy group (66.7%).
A total of 22 out of 30 patients (73.3%) with relapse were
treated with chemotherapy alone, with 13 patients in the
surveillance group, two in the chemotherapy group and
seven in the radiotherapy group. One (3.3%) and three
(10.0%) in the surveillance group were treated with radio-
therapy alone and with both chemotherapy and radiotherapy,
respectively, for the relapses in the retroperitonuem. Only
one patient, who relapsed after adjuvant radiotherapy, died
Table 2 Distribution of clinicopathological characteristics
Factor Post-orchiectomy management P*
Surveillance Chemotherapy Radiation
Tumor size
<5 cm 67 (56.3%) 14 (38.9%) 39 (44.8%) 0.101
5 cm 52 (43.7%) 22 (61.1%) 48 (55.2%)
Unknown 67 21 95
pT stage
pT1 133 (85.8%) 30 (63.8%) 109 (76.2%) 0.003
pT2 22 (14.2%) 17 (36.2%) 34 (23.8%)
Unknown 31 10 39
Anaplastic seminoma
Yes 4 (2.5%) 5 (10.9%) 10 (6.3%) 0.052
No 159 (97.5%) 41 (89.1%) 148 (93.7%)
Unknown 23 11 24
Syncytiotrophoblastic cell
Yes 10 (7.2%) 2 (5.4%) 6 (6.0%) 0.894
No 129 (92.8%) 35 (94.6%) 94 (94.0%)
Unknown 47 20 82
Lymphovascular invasion
Yes 12 (8.3%) 6 (16.7%) 19 (17.1%) 0.085
No 132 (91.7%) 30 (83.3%) 92 (82.9%)
Unknown 42 21 71
Rete testis invasion
Yes 12 (9.0%) 4 (10.5%) 5 (5.0%) 0.418
No 122 (91.0%) 34 (89.5%) 95 (95.0%)
Unknown 52 19 82
Spermatic cord invasion
Yes 3 (1.9%) 5 (10.6%) 10 (6.5%) 0.027
No 157 (98.1%) 42 (89.4%) 143 (93.5%)
Unknown 26 10 29
Elevation of serum LDH
Yes 63 (33.9%) 18 (31.6%) 61 (33.5%) 0.949
No 123 (66.1%) 39 (68.4%) 121 (66.5%)
Elevation of serum HCG
Yes 64 (34.4%) 28 (49.1%) 73 (40.1%) 0.123
No 122 (65.6%) 29 (50.9%) 109 (59.9%)
Elevation of LDH and/or HCG
Yes 80 (43.0%) 19 (33.3%) 68 (37.4%) 0.331
No 106 (57.0%) 38 (66.7%) 114 (62.6%)
*Pearson’s chi-square test. HCG, human chorionic gonadotropin; LDH, lactate dehydrogenase.
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was 100, 100 and 99.4% in the surveillance, chemotherapy
and radiotherapy groups, respectively.
Relapse-free survival and predictive factors
of relapse
RFS for 425 patients at 5 and 10 years was 93 and 89%,
respectively (Fig. 1a). RFS was signiﬁcantly better in the
chemotherapy and radiotherapy groups than in the surveil-
lance group (P = 0.0201, Fig. 1b). RFS in the surveillance,
chemotherapy and radiotherapy group was 90, 94 and 95%
at 5 years and 79, 94 and 94% at 10 years, respectively.
We carried out univariate and multivariate analyses using
various factors (Table 4). As a result, the post-orchiectomy
management (HR: 0.31 for chemotherapy, P = 0.119, HR:
0.40 for radiotherapy, P = 0.027, global P = 0.043) and rete
testis invasion (HR: 4.39, P = 0.010) were identiﬁed as inde-
pendent predictive factors of relapse. Because a relapse in
the contralateral testis is generally considered as a second
malignancy rather than a metastasis from original testicular
cancer, we carried out the same analyses by censoring the
cases with relapses in the contralateral testis. Rete testis
invasion was still identiﬁed as an independent predictive
factor (HR: 5.83, 95% conﬁdence intervals: 1.83–18.60,
P = 0.003). Subgroup analysis in the surveillance group
alone could not identify any predictive factors of RFS (data
not shown).
Discussion
Epidemiological evidence shows a clear trend toward a
worldwide increase in the incidence of TC during the past
three decades; this is also the case in Japan.
5 Meanwhile,
substantial differences in the incidence and trends have been
observed between geographical areas, as well as between
ethnic groups. TC incidence is lowest in Asia and Africa
compared with most Western countries. These differences
suggest a potential role of genetic, nutritional, sociological
or environmental factors in TC development.
5 These facts
encouraged us to investigate the differences, if any, in the
treatment outcomes for TC between Japan and the Western
countries.
In this regard, we sought to elucidate contemporary out-
comes for Japanese patients with stage I seminoma treated
with surveillance, adjuvant chemotherapy or adjuvant radio-
Table 3 Pattern of relapse and treatment at relapse
Post-orchiectomy management P*
Surveillance Chemotherapy Radiation
No. patients relapsed 19 2 9
Median time to relapse, months (range) 21.0 (2.5–101.3) 42.8 (29.8–55.8) 37.9 (3.8–173.1)
Time to relapse (no. patients, %)
0–2 years 12 (63.2%) 0 4 (44.4%)
2–5 years 3 (15.8%) 2 (100%) 3 (33.3%)
5–10 years 4 (21.1%) 0 1 (11.1%)
Over 10 years 0 0 1 (11.1%)
Site of relapse (no. patients, %)
Retroperitoneum 15 (78.9%) 2 (100%) 1 (11.1%) 0.001
Lung 1 (5.3%) 0 1 (11.1%) 1.000
Mediastinum 0 0 5 (55.6%) 0.002
Contralateral testis 4 (21.1%) 0 2 (22.2%) 1.000
Unknown 0 0 1 (11.1%) 0.367
2nd-line treatment at relapse (no. patients, %)
Chemotherapy 13 (68.4%) 2 (100%) 7 (77.8%)
Radiation 1 (5.3%) 0 0
Chemotherapy + radiation 3 (15.8%) 0 0
Orchiectomy alone 2 (10.5%) 0 0
Unknown 0 0 2 (22.2%)
Death during follow up (no. patients, %)
Death of the disease 0 0 1 (11.1%)
Death of other cause 0 0 0
*Fisher’s exact test.
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present study is relatively short, the results of RFS or the
relapse pattern after each type of the post-orchiectomy
management are equivalent to those found in previous
studies,
1,3,9–12 showing that the behavior of localized testicu-
lar seminoma is not different between Japanese and Western
populations.
If we can predict the patients at high risk of relapse,
adjuvant therapies, such as chemotherapy or radiotherapy,
could be applied to these selected patients. Therefore, we
sought to identify factors affecting RFS of the patients with
stage I seminoma. Multivariate analysis in the entire group
shows that the post-orchiectomy management and rete testis
invasion are independent predictive factors of RFS. Thus,
we suggest that patients with rete testis invasion should be
carefully monitored regardless of the post-orchiectomy
management. A large pooled analysis of patients with stage
I seminoma managed with surveillance, reported tumor size
and rete testis invasion as factors prognostic of relapse.
13
Furthermore, a risk-adapted management strategy has been
reported, with surveillance reserved for low-risk patients
and adjuvant therapy for intermediate and high-risk
patients.
14 Unfortunately, we could not identify any high-
risk group in the patients managed with surveillance, prob-
ably because of our relatively small sample size.
The present study shows a shift of the post-orchiectomy
management pattern in Japanese patients. Until 1990, adju-
vant radiotherapy was the predominant post-orchietomy
treatment. During the 1990s, the proportion of the patients
treated with a surveillance policy or adjuvant chemotherapy
was increasing. In the 2000s, a surveillance policy was pro-
vided to more than half of the TC patients. This change in
the management pattern might reﬂect on the positive and
negative aspects of each treatment. Adjuvant radiotherapy
has also been associated with late toxicities, such as
impaired fertility, development of second malignancies and
cardiovascular disease, despite its excellent cure rates.
15
Recently, single-agent carboplatin has been recognized as a
potential option for the post-orchiectomy management of
stage I seminoma with encouraging short-term results,
12,16,17
whereas long-term results on cure rates and toxicities are yet
to be clariﬁed.
18 The surveillance policy was introduced in
1983
19 and has become an accepted option for the manage-
ment of stage I seminoma, because subsequent prospective
studies consistently showed that 80–85% of patients are
cured by orchiectomy alone, and virtually all patients with
relapse can be salvaged by subsequent chemotherapy, mini-
mizing the burden of treatment.
3,10 The recent increase in
choosing the surveillance policy in Japan might also be
associated with our medical environment. First, we can
easily access big medical centers, such as university hospi-
tals, usually within an hour from our residence, which
makes follow up convenient for physicians and patients
during surveillance. Second, our medical costs are fully
covered by public insurance. This encourages us to undergo
high-tech imaging studies, such as multidetector row com-
puted tomography (CT) or
18F-ﬂuorodeoxy glucose-positron
emission tomography to detect disease relapse at an early
stage. Interestingly, the present study showed that the
patients treated with adjuvant therapy also accepted a rigor-
ous check-up schedule, similar to the patients in a surveil-
lance policy (Table 5). Thus, regarding medical costs, there
was no advantage that the patients with adjuvant therapies
had over those with surveillance policy. This also might
partly explain the reasons for their choice of surveillance
policy. During the study period between 1985 and 2006, the
sensitivity of CT for detection of smaller lymph nodes has
been undoubtedly improved as a result of the introduction of
multislice CT. It might improve the accuracy of staging in
patients with stage I seminoma, which might result in the
recent increase in the choice of surveillance policy.
However, we should recognize that the microscopic deposits
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Fig. 1 (a) Relapse-free survival of 425 patients with stage I
seminoma. (b) Relapse-free survival of patients managed with
surveillance,chemotherapyorradiotherapyafterorchiectomy.
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Factor Category No.
patients
No.
relapse
Univariate Multivariate
Hazard
ratio
95% CI P* Hazard
ratio
95% CI P*
Age at orchiectomy 36 years 215 20 1
>36 years 206 10 0.52 0.24–1.10 0.088
Post-orchiectomy management Surveillance 186 19 1 0.028** 1 0.043**
Chemotherapy 57 2 0.29 0.07–1.26 0.098 0.31 0.07–1.35 0.119
Radiation 182 9 0.38 0.17–0.85 0.018 0.40 0.18–0.90 0.027
Tumor size 5 cm 120 5 1
>5 cm 122 10 1.93 0.66–5.65 0.232
Elevation of LDH and/or HCG No 167 8 1
Yes 258 22 1.83 0.82–4.12 0.142
Elevation of LDH No 283 18 1
Yes 142 12 1.42 0.68–2.94 0.349
Elevation of HCG No 260 17 1
Yes 165 13 1.24 0.60–2.55 0.564
pT stage pT1 272 18 1
pT2 73 4 0.85 0.29–2.51 0.765
Anaplastic seminoma No 348 21 1
Yes 19 3 2.17 0.65–7.29 0.211
Syncytiotrophoblastic cell No 258 17 1
Yes 18 2 2.09 0.48–9.13 0.327
Lymphovascular invasion No 254 17 1
Yes 37 3 1.17 0.34–4.01 0.798
Rete testis invasion No 251 14 1 1
Yes 21 4 5.44 1.73–17.1 0.004 4.39 1.42–13.6 0.010
Spermatic cord invasion No 342 22 1
Yes 18 2 1.59 0.37–6.78 0.530
*Wald test based on Cox proportional hazard model. **P-values for global association. HCG, human chorionic gonadotropin; LDH,
lactate dehydrogenase.
Table 5 Post-treatment work-up interval
Follow up timing Modality Median work-up interval, months (range)
Surveillance Chemotherapy Radiation
Up to 2 years Tumor marker 3 (1–12) 3 (1–6) 3 (1–6)
Chest X-ray 3 (1–12) 3 (1–6) 3 (1–12)
Chest CT 4 (3–12) 6 (2–12) 6 (2–12)
Abdominal CT 4 (1–12) 4.5 (2–12) 6 (2–12)
Up to 5 years Tumor marker 6 (2–12) 6 (1–6) 6 (2–12)
Chest X-ray 6 (3–12) 6 (2–12) 6 (3–12)
Chest CT 6 (3–12) 6 (3–12) 6 (3–12)
Abdominal CT 6 (3–12) 6 (3–12) 6 (3–12)
Up to 10 years Tumor marker 12 (4–12) 12 (2–12) 6 (3–12)
Chest X-ray 12 (6–12) 12 (6–12) 12 (4–12)
Chest CT 12 (6–12) 12 (6–12) 12 (6–12)
Abdominal CT 12 (6–12) 12 (6–12) 12 (6–12)
CT, computed tomography.
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tumoral and inﬂammatory adenopathy are beyond the scope
of CT and false-negative examinations are therefore inevi-
table.
20 In the present study, we cannot draw any deﬁnitive
conclusion on this issue, because CT devices were not
uniform among the hospitals.
The present study unexpectedly disclosed a potential
problem in the management of patients with stage I semi-
noma in Japan. In all, 240 of 425 patients (56.5%) were lost
to follow up at the entry of the present study, with a mean
follow up of approximately 5 years. Surprisingly, 47.3%
(88/186) of the patients managed with surveillance were lost
to follow up, with a mean follow up of approximately
4.5 years. Because of the easy accessibility to hospitals in
Japan and the compliant nature of the Japanese patients
toward physicians, we have long believed that most TC
patients are routinely followed up for the long term. As we
did not plan to include the reasons for discontinuing follow
up in this survey, we cannot ﬁnd any deﬁnitive causes for
loss-to-follow up. However, it is noteworthy that half of the
patients in the present study were in the age of 35 years or
younger. We speculate that young adults in this age group
could not afford medical costs during their follow up,
because their incomes are usually low, even if their medical
costs are fully covered by insurance.
21 Another speculation
is that these young adults might have more opportunities to
move to other cities for their college education or for better
employment prospects. Guidelines recommend a yearly
follow up for the long term, up to 10 years as a minimum
follow up duration, not only for post-orchiectomy surveil-
lance, but also for radiotherapy or chemotherapy, because
late relapses have been observed to occur.
22,23 Although late
relapses are more frequently observed during surveillance
than after adjuvant chemotherapy or radiotherapy,
24 a sur-
veillance policy in stage I seminoma is highly effective in a
motivated center, providing excellent long-term survival
with minimal morbidity and good cost-effectiveness.
25 We
should keep in mind that a high level of motivation of both
patients and physicians is required for effective long-term
follow up when we choose surveillance policy in the man-
agement of patients with stage I seminoma. In addition, we
should also try to minimize the number of CT studies during
the follow up, even in the surveillance policy if possible,
particularly in younger individuals, because the cumulative
radiation exposure associated with multiple CT studies has
the potential for causing secondary malignancies in long-
term survivors.
26,27 In this context, the follow-up schedule
described in EAU guidelines can be considered as a
minimum requirement, which recommends abdominopelvic
CT scans twice a year in the ﬁrst 2 years and once a year
thereafter up to 10 years.
22
The limitations of the present study are its retrospective
nature and the relatively short median follow up, which
might lower the quality of analysis. However, the results
obtained in the present study are comparable to those in
previously published reports.
1,3,9–12 We should carry out a
prospective analysis on the long-term outcome of patients
with stage I seminoma, and we believe that the present study
provides not only baseline data for a prospective study, but
also information for the patients in choosing the post-
orchiectomy management.
In conclusion, the present study is the ﬁrst large-scale
retrospective clinical study of TC in Japan, and shows that
the outcome of Japanese patients with stage I seminoma is
similar to the outcome in previously published reports in
Western countries. Surveillance policy is becoming a
popular option in Japan, although the relapse rate in patients
opting for surveillance policy is somewhat higher than in
those opting for adjuvant chemotherapy or radiotherapy.
Rete testis invasion is an independent predictive factor asso-
ciated with relapse regardless of the post-orchiectomy man-
agement; patients with rete testis invasion should be
carefully monitored for relapse. Long-term monitoring of
the patients up to at least 10 years is mandatory for the
detection of late relapse.
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